|
FR2724320B1
(fr)
|
1994-09-13 |
1996-12-20 |
Transgene Sa |
Nouvel implant pour le traitement des maladies acquises
|
|
BR9710811A
(pt)
|
1996-05-22 |
1999-08-17 |
Novopharm Biotech Inc |
Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
HK1043608B
(en)
|
1999-08-17 |
2007-12-07 |
Biogen Ma Inc. |
Baff receptor (bcma), an immunoregulatory agent
|
|
AU2001263114A1
(en)
|
2000-05-12 |
2001-11-26 |
Amgen Inc |
Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
|
|
AU2002238052A1
(en)
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
JP2003111595A
(ja)
|
2001-06-25 |
2003-04-15 |
Kyogo Ito |
腫瘍抗原
|
|
AU2003221256A1
(en)
|
2002-02-21 |
2003-09-09 |
Biogen Idec Ma Inc. |
Use of bcma as an immunoregulatory agent
|
|
US7820166B2
(en)
|
2002-10-11 |
2010-10-26 |
Micromet Ag |
Potent T cell modulating molecules
|
|
AU2004242845B2
(en)
|
2003-05-31 |
2011-06-02 |
Amgen Research (Munich) Gmbh |
Human-anti-human CD3 binding molecules
|
|
US8076459B2
(en)
|
2003-10-16 |
2011-12-13 |
Micromet Ag |
Multispecfic deimmunized CD3-binders
|
|
WO2005042009A1
(en)
|
2003-10-20 |
2005-05-12 |
Biogen Idec Ma Inc. |
Therapeutic regimens for baff antagonists
|
|
AU2005318086B2
(en)
|
2004-12-23 |
2011-07-07 |
Merck Serono Sa |
BCMA polypeptides and uses thereof
|
|
PT1853718E
(pt)
|
2005-02-15 |
2015-11-12 |
Univ Duke |
Anticorpos anti-cd19 e usos em oncologia
|
|
JP2009521474A
(ja)
|
2005-12-21 |
2009-06-04 |
メディミューン，エルエルシー |
ＥｐｈＡ２ＢｉＴＥ分子およびその使用
|
|
JP2009544761A
(ja)
|
2006-06-14 |
2009-12-17 |
マクロジェニクス，インコーポレーテッド |
低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
|
|
CA2676529C
(en)
|
2007-01-24 |
2014-03-25 |
Kyowa Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
CA2681728C
(en)
|
2007-03-27 |
2015-12-22 |
Zymogenetics, Inc. |
Combination of blys and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
|
|
US8460647B2
(en)
|
2007-04-20 |
2013-06-11 |
Amgen Inc. |
Pre-ligand assembly domain of the IL-17 receptor
|
|
KR101837053B1
(ko)
|
2008-10-01 |
2018-03-12 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 ＰＳＣＡｘＣＤ３, ＣＤ19ｘＣＤ3, ｃ-ＭＥＴｘＣＤ3, 엔도시알린ｘＣＤ3, ＥｐＣＡＭｘＣＤ3, ＩＧＦ-1ＲｘＣＤ3 또는 ＦＡＰαｘＣＤ3 이중특이적 단일쇄 항체
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
CN102421801B
(zh)
|
2009-03-10 |
2016-03-16 |
比奥根Ma公司 |
抗-bcma抗体
|
|
CA2793753C
(en)
|
2010-03-26 |
2018-06-05 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
|
JP5985481B2
(ja)
|
2010-09-01 |
2016-09-06 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗イディオタイプ抗体の迅速な産生
|
|
EP3974453A3
(en)
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
AR085138A1
(es)
|
2011-02-04 |
2013-09-11 |
Genentech Inc |
VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
|
|
WO2012118622A1
(en)
|
2011-02-19 |
2012-09-07 |
Baylor Research Institute |
Diagnostic and therapeutic uses for b cell maturation antigen
|
|
TWI622597B
(zh)
|
2011-03-28 |
2018-05-01 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
|
US20130101599A1
(en)
|
2011-04-21 |
2013-04-25 |
Boehringer Ingelheim International Gmbh |
Bcma-based stratification and therapy for multiple myeloma patients
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
EP2714737A1
(en)
|
2011-05-27 |
2014-04-09 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
CN104203982B
(zh)
|
2011-10-28 |
2018-08-31 |
特瓦制药澳大利亚私人有限公司 |
多肽构建体及其用途
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
CN104203981A
(zh)
|
2011-12-19 |
2014-12-10 |
合成免疫股份有限公司 |
双特异性抗体分子
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
CA2866699A1
(en)
|
2012-03-09 |
2013-09-12 |
Ucl Business Plc |
Chemical modification of antibodies
|
|
KR20150029714A
(ko)
|
2012-07-13 |
2015-03-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
BR112016000666A2
(pt)
|
2013-07-12 |
2017-10-03 |
Zymeworks Inc |
Constructos de ligação de antígeno cd3 e cd19 biespecíficos
|
|
US9907820B2
(en)
|
2013-10-25 |
2018-03-06 |
Board Of Regents, The University Of Texas System |
Polyclonal gamma delta T cells for immunotherapy
|
|
ES2959480T3
(es)
|
2014-02-07 |
2024-02-26 |
Univ Mcmaster |
Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
WO2016180468A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-18.2-specific immunoreceptors and t cell epitopes
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
EP3377523A4
(en)
|
2015-11-19 |
2019-06-19 |
The Regents of The University of California |
CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
|
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
|
EP3493827A4
(en)
|
2016-08-04 |
2020-02-26 |
Memorial Sloan-Kettering Cancer Center |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
|
|
CN108250302A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
EP3694997A4
(en)
|
2017-10-12 |
2021-06-30 |
Mcmaster University |
T cell-antigen coupler with y182t mutation and methods and uses thereof
|
|
US20220127570A1
(en)
*
|
2018-05-03 |
2022-04-28 |
Cafa Therapeutics Limited |
Immune effector cell and use thereof
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
CN112689642B
(zh)
|
2018-07-17 |
2025-01-17 |
特拉姆维拉免疫美国有限公司 |
具有各种不同的构建物优化的t细胞抗原偶联物
|
|
US11110123B2
(en)
*
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
JP2022523749A
(ja)
|
2019-02-01 |
2022-04-26 |
クレージュ メディカル カンパニー，リミテッド |
Ｔｃｒ融合タンパク質およびｔｃｒ融合タンパク質を発現する細胞
|
|
CA3141504A1
(en)
*
|
2019-05-24 |
2020-12-03 |
Sanyou Biopharmaceuticals Co., Ltd. |
Novel cldn18.2 binding molecule
|
|
AU2022283819A1
(en)
|
2021-06-01 |
2024-01-04 |
Triumvira Immunologics Usa, Inc. |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
*
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|